Does Astronics Corporation (ATRO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Beth Kindig says "any dips on China should be bought" after Nvidia (NVDA) reports earnings. She considers sales to the country insignificant compared to the upside potential Nvidia's Blackwell will offer for the A.I.

US Treasury Secretary Scott Bessent on Wednesday dismissed the notion that the US government would take an ownership stake in semiconductor company Nvidia Corp (NASDAQ:NVDA, ETR:NVD). "I don't think Nvidia needs financial support, so that seems not on the table right now," he told Fox Business' "Mornings with Maria" program.

Centene's stock is deeply undervalued after a 60% drop, with key valuation multiples 50%-70% below historical averages. Despite 2025 headwinds and EPS guidance cuts, Centene remains profitable, well-diversified, and financially stable with strong liquidity. Long-term demographic trends and Centene's history of resilience support a sharp EPS rebound in 2026 and 2027.

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of iRobot Corporation (NASDAQ: IRBT) between January 29, 2024 and March 11, 2025, both dates inclusive (the “Class Period”), of the important September 5, 2025 lead plaintiff deadline.

Occidental leverages low-cost operations, top-tier assets and strong earnings surprises to drive growth and resilience in volatile markets.

Buy NFLX despite 40.8x P/E. Ad transformation, robust content investments and strong cash generation drive multi-year outperformance.

NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of iRobot Corporation (NASDAQ: IRBT) between January 29, 2024 and March 11, 2025, both dates inclusive (the "Class Period"), of the important September 5, 2025 lead plaintiff deadline. So What: If you purchased iRobot securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NexPoint Residential Trust is an apartment REIT focused on Sun Belt markets such as Phoenix, South Florida, Dallas/Fort Worth, and Atlanta. Core FFO growth continued in Q2 2025, although the key driving factor, share repurchases, appears unsustainable in light of rising leverage. Operational performance remains challenging, with no immediate turnaround expected in H2 2025.

BXMT's Q2 2025 results were largely as expected, with minor BV fluctuations and modest core earnings outperformance driven by higher-than-anticipated loan originations. The company shifted to a more aggressive loan origination strategy, signaling a potential stabilization in portfolio size, but credit risk remains elevated with new non-accrual loans. I maintain a risk/performance rating of 4.5, as BXMT is still working through legacy troubled loans and faces ongoing challenges in office and multifamily segments.

NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between March 24, 2023 and May 14, 2025, both dates inclusive (the "Class Period"), of the important September 12, 2025 lead plaintiff deadline.

REX American Resources Corporation (NYSE:REX ) Q2 2025 Earnings Call August 27, 2025 11:00 AM ET Company Participants Douglas L. Bruggeman - VP of Finance, CFO & Treasurer Stuart A.

AAL faces margin pressure as high labor costs and weak revenues weigh on the outlook despite second-quarter gains.

UPS hikes import fees as the United States ends duty-free exemptions, but weak volumes, high costs and dividend strain weigh on the stock.

There have been some significant acquisitions in the mid-cap biotech space over the past couple of months. In today's column, I highlight two mid-cap biotech names that should have bright futures on their own, but would make logical buyout candidates: Abivax Société Anonyme and MoonLake Immunotherapeutics. Both have late-stage assets targeting large markets, and both companies should file for their first FDA approvals in 2026.

NEW YORK and MAINZ, GERMANY, AUGUST 27, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.2

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts the.

High-quality oil stocks like Schlumberger, Halliburton, and Devon Energy have seen significant declines but likely bottomed in early April. Oil prices are unlikely to stay depressed, with potential for a substantial move higher by 2026 as market dynamics and political factors shift. Saudi Arabia's need for higher oil prices and anticipated Fed rate cuts should support a rebound in oil prices and sector equities.

SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- On August 20, 2025, investors in James Hardie Industries plc (NYSE: JHX) saw the price of their shares crash $9.79 (-34%) after the company reported its Q1 2026 financial results and revealed problems with its North America business, its largest reporting segment.

AI hype that has helped push U.S. stocks to fresh records this year has driven an explosion in leveraged single stock exchange-traded funds, a universe of speculative products that is likely to be tested by Nvidia's NVDA.O Wednesday earnings.